Practice Management News

Most patients and health care providers would agree that interdisciplinary care leads to the most successful patient outcomes.

For individuals diagnosed with treatment-resistant depression, response and remission rates for IV ketamine and intranasal esketamine were similar, but remission time was quicker with the former compared with the latter.

The Biden administration recently released its proposed 2024 federal budget, which would extend the solvency of Medicare by 25 years while reducing behavioral health and medication costs for beneficiaries.

The FDA announced it does not plan to hold an advisory committee meeting on Sage and Biogen’s new drug application for zuranolone to treat major depressive disorder and postpartum depression in adults.

HHS announced it has awarded $250,000 in emergency funding to Community Action Agency of Columbiana County to assist with behavioral and other health concerns for those affected by the train derailment in East Palestine, Ohio.

The FDA has granted breakthrough device designation to a Finnish medical company for its portable, patient-administered neuromodulation device to treat depression.

Results of a recently released poll found that 86% of U.S. adults believe pet ownership has a positive impact on their mental health.

A mental health nonprofit has announced 11 companies will make up the inaugural cohort of a program that aims to help startups improve the lives of those with challenges relating to mental health conditions.

Researchers identified ketamine as a possible treatment for cocaine use disorder using artificial intelligence and professional expertise, according to findings published in the journal Addiction.

A noninvasive focused ultrasound technology was used in an FDA-approved clinical trial to treat Alzheimer’s disease, according to a press release.